Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Details Narrative)

v3.22.2.2
Stock-Based Compensation (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jan. 07, 2022
Mar. 31, 2022
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Proceeds from common stock       $ 55,016,000  
Employee Stock Purchase Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock capital shares reserved for future issuance       1,750,000    
Share-based payment award, number of shares available for grant       931,841    
Number of common stock purchased   194,240 203,480      
Proceeds from common stock   $ 217 $ 304      
Employee Stock Purchase Plan [Member] | Lucid Diagnostics Inc [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock capital shares reserved for future issuance       500,000    
2014 Equity Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock capital shares reserved for future issuance       16,352,807    
Share-based payment award, number of shares available for grant       2,830,092    
Number of restricted stock awards granted outstanding       600,854    
Number of stock options outstanding       600,854    
2018 Stock Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock capital shares reserved for future issuance       9,144,000    
Share-based payment award, number of shares available for grant       3,932,802    
Number of restricted stock awards granted outstanding       473,300    
Number of stock options outstanding       473,300    
2018 Equity Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Number of restricted stock awards granted outstanding       50,000   50,000
Number of stock options outstanding       2,459,666 [1]   1,419,242
Weighted average fair value of stock options       $ 1.48    
2018 Equity Plan [Member] | Restricted Stock [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Number of restricted stock, granted 320,000          
Vesting period description restricted stock awards having a single vesting date on January 7, 2025          
Fair value of restricted stock granted $ 1,400,000          
[1] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics Inc. 2018 Equity Plan. as of June 30, 2022 and December 31, 2021.